AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30247316 — intervention group
Group type: EXPERIMENTAL
Intervention: QFN-CMV directed valganciclovir prophylaxis (5 months)
Number of subjects: 118
Study 30247316 — intervention group
Group type: COMPARATOR
Intervention: No protective immunity (negative QFN-CMV assay)
Number of subjects: 118
Study 30247316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceasing antiviral prophylaxis at 11 months with negative assay
Number of subjects: 118
Study 27696628 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-ARM1 vs HD-ARM2
Number of subjects: 36
Study 27696628 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-ARM1 vs HD-ARM3
Number of subjects: 36
Study 27696628 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-ARM1 vs HR-ARM
Number of subjects: 36
Study 25528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of health worker training, adolescent-friendly facility improvements, and broad information dissemination via community, schools, and mass media.
Number of subjects: 21
Study 25528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-generation activities.
Number of subjects: 21
Study 25528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental and community gatekeepers' approval of SRHS for adolescents.
Number of subjects: 21
Study 25528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-facility-based strategies delivered through mixed-use youth centers.
Number of subjects: 21
Study 25528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent friendliness training for health workers.
Number of subjects: 21
Study 23561918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of saphenous vein grafts (SVGs)
Number of subjects: 80
Study 21719756 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous schedule (daily coverage by a single intensivist in half-month rotations)
Number of subjects: 1900
Study 21719756 — intervention group
Group type: COMPARATOR
Intervention: Interrupted schedule (weekday coverage by a single intensivist with weekend cross-coverage by colleagues)
Number of subjects: 1900
Study 21719756 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous schedule
Number of subjects: 1900
Study 19748319 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 250 microg subcutaneously every other day for 2 years (early treatment)
Number of subjects: 468
Study 19748319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed treatment)
Number of subjects: 468
Study 19748319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (early and delayed treatment)
Number of subjects: 468
Study 17845658 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 20
Study 17845658 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 25696357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice-daily plus dietary counselling
Number of subjects: 0
Study 25696357 — intervention group
Group type: COMPARATOR
Intervention: Dietary counselling alone
Number of subjects: 0
Study 11483172 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming pictures in the context of same-category items
Number of subjects: 0
Study 11483172 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming words in the context of same-category items
Number of subjects: 0
Study 11483172 — intervention group
Group type: EXPERIMENTAL
Intervention: Producing words with their corresponding determiner
Number of subjects: 0
Study 9773735 — intervention group
Group type: COMPARATOR
Intervention: Premeal human regular insulin before lunch and supper at unchanged dose
Number of subjects: 12
Study 9773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal lispro (unchanged dose) at lunchtime and dinner
Number of subjects: 12
Study 9773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐lunch reduced‐dose lispro (70%) before lunch and supper with supplemental lunchtime NPH and with a 6‐h interval until dinner
Number of subjects: 12
Study 9773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐lunch reduced‐dose lispro (70%) before lunch and supper with supplemental lunchtime NPH and with a 8‐h interval until dinner
Number of subjects: 12
Study 9773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual‐dose lispro alone
Number of subjects: 12
Study 9773735 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 12
Study 9773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced‐dose lispro plus NPH
Number of subjects: 12
Study 9773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro plus NPH
Number of subjects: 12
Study 7848900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg i.v.)
Number of subjects: 30
Study 7848900 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg i.v.)
Number of subjects: 30
Study 7848900 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 or 100 mg/day)
Number of subjects: 30
Study 3136828 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of 40 mg mitomycin C in 40 ml of water
Number of subjects: 457
Study 3136828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple instillations of mitomycin C (single instillation plus four further instillations)
Number of subjects: 457
Study 3136828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instillation of mitomycin C)
Number of subjects: 457
Study 31840286 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical smartphone app
Number of subjects: 293
Study 31840286 — intervention group
Group type: COMPARATOR
Intervention: Traditional booklet-based and verbal instructions (Control)
Number of subjects: 293
Study 29549243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 72
Study 29549243 — intervention group
Group type: EXPERIMENTAL
Intervention: High cereal fiber diet (HCF)
Number of subjects: 72
Study 29549243 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately increased cereal fiber and protein diet (MIX)
Number of subjects: 72
Study 29549243 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 72
Study 28657529 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002 (50 mg once daily for 12 weeks)
Number of subjects: 60
Study 28657529 — intervention group
Group type: COMPARATOR
Intervention: GS/CS (375/300 mg once daily for 12 weeks)
Number of subjects: 60
Study 25555621 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT+XR-NTX
Number of subjects: 125
Study 25555621 — intervention group
Group type: COMPARATOR
Intervention: BNT+placebo injection
Number of subjects: 125
Study 25555621 — intervention group
Group type: EXPERIMENTAL
Intervention: CE+XR-NTX
Number of subjects: 125
Study 25555621 — intervention group
Group type: COMPARATOR
Intervention: CE+placebo injection
Number of subjects: 125
Study 23207887 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented verbal feedback during countermovement vertical jump (CMVJ) protocol
Number of subjects: 14
Study 23207887 — intervention group
Group type: COMPARATOR
Intervention: No feedback during countermovement vertical jump (CMVJ) protocol
Number of subjects: 14
Study 21939549 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile (270 mg twice daily)
Number of subjects: 34
Study 21939549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18413195 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 34
Study 18413195 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 34
Study 16646124 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic brain injury (TBI)
Number of subjects: 127
Study 16646124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 12544677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (equine conjugated estrogens 0.625 mg/day + dydrogesterone 5 mg/day in a continuous combined regimen)
Number of subjects: 80
Study 12544677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with hormones)
Number of subjects: 80
Study 10845505 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 42
Study 10845505 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42
Study 8996576 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate combined with cisplatin
Number of subjects: 2
Study 8996576 — intervention group
Group type: COMPARATOR
Intervention: Etoposide combined with cisplatin
Number of subjects: 2
Study 1467031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise for 20 minutes a day, five days a week for eight weeks at 70%-80% of maximum heart rate
Number of subjects: 22
Study 30695790 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel (control group)
Number of subjects: 2610
Study 30695790 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (guided de-escalation group)
Number of subjects: 2610
Study 29936125 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychotherapy for smoking cessation with transdermal nicotine patch and text messaging support
Number of subjects: 340
Study 29936125 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral smoking cessation counseling with transdermal nicotine patch and text messaging support
Number of subjects: 340
Study 26630313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal conbercept injection
Number of subjects: 36
Study 26630313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no conbercept)
Number of subjects: 36
Study 25137875 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic specific formula (DSF)
Number of subjects: 30
Study 25137875 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 30
Study 22508825 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC (daunorubicin plus cytarabine plus cladribine)
Number of subjects: 652
Study 22508825 — intervention group
Group type: COMPARATOR
Intervention: DAF (daunorubicin plus cytarabine plus fludarabine)
Number of subjects: 652
Study 20613556 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Number of subjects: 24
Study 20613556 — intervention group
Group type: COMPARATOR
Intervention: Polydioxanone (PDS) foil
Number of subjects: 24
Study 17389691 — intervention group
Group type: EXPERIMENTAL
Intervention: Domino model
Number of subjects: 58
Study 17389691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clements 250 model
Number of subjects: 58
Study 17389691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hijazi model
Number of subjects: 58
Study 17389691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clements 125 model
Number of subjects: 58
Study 15632877 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 12227885 — intervention group
Group type: EXPERIMENTAL
Intervention: medrogestone (10 mg/day)
Number of subjects: 31
Study 12227885 — intervention group
Group type: EXPERIMENTAL
Intervention: dydrogesterone (10 mg/day)
Number of subjects: 31
Study 12227885 — intervention group
Group type: EXPERIMENTAL
Intervention: medrogestone and dydrogesterone
Number of subjects: 31
Study 9848597 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft tensioned at 20 N
Number of subjects: 38
Study 9848597 — intervention group
Group type: COMPARATOR
Intervention: Graft tensioned at 40 N
Number of subjects: 38
Study 8090293 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 12
Study 8090293 — intervention group
Group type: COMPARATOR
Intervention: Distal arterial reconstruction (femoro-distal bypass)
Number of subjects: 12
Study 2806981 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nalbuphine
Number of subjects: 40
Study 2806981 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of morphine
Number of subjects: 40
Study 896016 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor task with the left arm
Number of subjects: 102
Study 896016 — intervention group
Group type: COMPARATOR
Intervention: Motor task with the right arm
Number of subjects: 102
Study 31260468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg diluted to 5 ml normal saline)
Number of subjects: 110
Study 31260468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml normal saline)
Number of subjects: 110
Study 31260468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 110
Study 28414061 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 28414061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26183669 — intervention group
Group type: EXPERIMENTAL
Intervention: VVSymQ® instrument (patient-reported outcome measure)
Number of subjects: 0
Study 26183669 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic daily diary incorporating VVSymQ® instrument
Number of subjects: 0
Study 24528569 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (one face-to-face consultation and one via videoconference)
Number of subjects: 160
Study 24528569 — intervention group
Group type: COMPARATOR
Intervention: Reference group (two sequential face-to-face consultations)
Number of subjects: 160
Study 21760497 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconference support group
Number of subjects: 0
Study 19539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 72
Study 19539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 72
Study 19539524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18246681 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part massotherapy
Number of subjects: 200
Study 18246681 — intervention group
Group type: COMPARATOR
Intervention: Guipi Wan (Pill for Invigorating the Spleen and Nourishing the Heart)
Number of subjects: 200
Study 14971630 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-luteal phase
Number of subjects: 15
Study 14971630 — intervention group
Group type: COMPARATOR
Intervention: Mid-follicular phase
Number of subjects: 15
Study 15046708 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitors
Number of subjects: 0
Study 15046708 — intervention group
Group type: EXPERIMENTAL
Intervention: Metalloproteinase inhibitors
Number of subjects: 0
Study 15046708 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of prostate cancer cell-endothelial cell interactions
Number of subjects: 0
Study 15046708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 10220667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 30
Study 10220667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 30
Study 10220667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 30
Study 7799117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 35
Study 7799117 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)
Number of subjects: 35
Study 2102144 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental chemical ablation using 80% phenol
Number of subjects: 422
Study 2102144 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental chemical ablation using 10% sodium hydroxide
Number of subjects: 422
Study 2102144 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative pain
Number of subjects: 422
Study 7396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine after epidural anaesthesia with diazepam sedation
Number of subjects: 38
Study 7396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine after neuroleptanaesthesia
Number of subjects: 38
Study 7396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine and pethidine after neuroleptanaesthesia
Number of subjects: 38
Study 7396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine after halothane anaesthesia
Number of subjects: 38
Study 7396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine after halothane anaesthesia
Number of subjects: 38
Study 7396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine and pethidine after epidural anaesthesia
Number of subjects: 38
Study 31169125 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-loaded nanoparticles
Number of subjects: 0
Study 31169125 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28277235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric radiologist
Number of subjects: 602
Study 28277235 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-standing pediatric hospital (FSPH)
Number of subjects: 602
Study 28277235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric 'hospital within a hospital' (PHWH)
Number of subjects: 602
Study 28277235 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pediatric hospital (NPH)
Number of subjects: 602
Study 28277235 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient radiology facility (ORF)
Number of subjects: 602
Study 26978413 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg/day
Number of subjects: 80
Study 26978413 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 100 mg/day
Number of subjects: 80
Study 26978413 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 100 mg/day
Number of subjects: 80
Study 26978413 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg/day
Number of subjects: 80
Study 25111430 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant-other-enhanced motivational intervention (SOMI)
Number of subjects: 406
Study 25111430 — intervention group
Group type: COMPARATOR
Intervention: Individual motivational intervention (IMI)
Number of subjects: 406
Study 22455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (GPT) plus 50 mg sildenafil on-demand
Number of subjects: 30
Study 22455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (GPT) exclusively
Number of subjects: 30
Study 22455403 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sildenafil on-demand exclusively
Number of subjects: 30
Study 19051030 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 8
Study 19051030 — intervention group
Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 8
Study 17559108 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting nitinol stents
Number of subjects: 0
Study 17559108 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study 15569863 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase (125 microg/kg)
Number of subjects: 104
Study 15569863 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase (62.5 microg/kg)
Number of subjects: 104
Study 15569863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 15569863 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase (overall)
Number of subjects: 104
Study 15569863 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 104
Study 11963733 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 micrograms)
Number of subjects: 15
Study 11963733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9804600 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH), end‐tidal PO2 (PETO2) = 55 Torr, PETCO2 held at normal prehypoxic value
Number of subjects: 10
Study 9804600 — intervention group
Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH), PETO2 = 55 Torr
Number of subjects: 10
Study 9804600 — intervention group
Group type: COMPARATOR
Intervention: Control (C), air breathing
Number of subjects: 10
Study 7759668 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatments
Number of subjects: 0
Study 7759668 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological issues in treatment research
Number of subjects: 0
Study 2729154 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water technique (dlwEE)
Number of subjects: 6
Study 2729154 — intervention group
Group type: COMPARATOR
Intervention: Energy expenditure estimated from individual diary records of physical activity
Number of subjects: 6
Study 2729154 — intervention group
Group type: COMPARATOR
Intervention: Energy expenditure estimated from 24‐h heart rate recordings
Number of subjects: 6
Study 2729154 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily energy intake
Number of subjects: 6
Study 88853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin therapy
Number of subjects: 55
Study 88853 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 55
Study 88853 — intervention group
Group type: COMPARATOR
Intervention: Cryo-surgical treatment
Number of subjects: 55
Study 31958281 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4, SB2, SB5 (biosimilars of etanercept, infliximab, and adalimumab)
Number of subjects: 1265
Study 31958281 — intervention group
Group type: COMPARATOR
Intervention: Control group (remission)
Number of subjects: 1265
Study 31237569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation mobile app 'Calm' for 8 weeks, participants asked to meditate at least 10 minutes per day.
Number of subjects: 88
Study 31237569 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 88
Study 28158510 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based renal artery denervation (RDN)
Number of subjects: 1103
Study 26288230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 176
Study 26288230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 23340449 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO+sulindac treatment in dietary polyamine quartiles 1-3
Number of subjects: 267
Study 23340449 — intervention group
Group type: COMPARATOR
Intervention: Dietary polyamine quartile 4
Number of subjects: 267
Study 21658349 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 kcal per kg per week (KKW) exercise expenditure for 12 weeks
Number of subjects: 126
Study 21658349 — intervention group
Group type: COMPARATOR
Intervention: 4 KKW exercise expenditure for 12 weeks
Number of subjects: 126
Study 21658349 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 KKW exercise (women)
Number of subjects: 126